A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment
A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

A Study to Evaluate Imetalstat (JNJ-63935937) in Transfusion-Dependent Subjects with IPSS low or intermediate -1 Risk Myelodysplastic Syndrome (MDS) that is Relapsed/Refractory to Erythropoiesis- Stimulating Agent (ESA) Treatment

Read more
Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry MDS/AML Disease Registry

Read more
Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent
Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Read more